Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0812/ Duration of Treatment: 12 Weeks · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0812 / Duration of Treatment: 12 Weeks | DRUG | - |
| Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks | DRUG | - |
Inclusion Criteria: * Patient has had diagnosis of RA made at least 6 months prior to study start and was greater than 16 years of age when diagnosed * Patient has active RA with a minimum level of disease activity including at least 10 swollen joints and 10 tender or painful joints * Excepting rhe...
MK0812 is an investigational small molecule being studied for the treatment of rheumatoid arthritis, a form of arthritis. It is in Phase 2 clinical development and has not been approved by regulatory authorities.
MK0812 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company conducted a Phase 2 clinical trial of the drug in patients with rheumatoid arthritis.
MK0812 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug, meaning it is not yet approved for any use.
MK0812 has been studied in one completed Phase 2 clinical trial, identified as NCT00542022, titled 'Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)'. This trial enrolled 149 participants.
No, MK0812 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for rheumatoid arthritis, but it has not received regulatory approval.